Form 4 for PALI PALISADE BIO, INC.
Accepted 2024-05-22 00:00:00 ET · period of report 2024-05-20 · accession 0001493152-24-021045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-22 | 2024-05-20 | PALI | Finley John David | CEO, CFO, Dir | A - Grant | $4.97 | +666 | 7,437 | +10% | +$3,310 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.01 | 2024-05-20 | A | A | 666 | $4.97 | 7,437 | D | — | — | (F1) Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from November 21, 2023 through May 20, 2024. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on May 20, 2024. |